We refer to the announcements dated 7 September 2026 and 22 September 2026 in relation to the Proposed Strategic Equity Participation Plan. Unless otherwise defined, the definitions set out in the previous announcements shall apply herein.

On behalf of the Board, UOBKH wishes to announce that Bursa Securities has, vide its letter dated 25 September 2026, resolved to approve the listing of and quotation for up to 16,658,252 new Cengild Medical Shares to be issued pursuant to the Proposed Strategic Equity Participation Plan on the ACE Market of Bursa Securities, subject to the following conditions:-

(i) Cengild Medical and UOBKH must fully comply with the relevant provisions under the ACE Market Listing Requirements of Bursa Securities pertaining to the implementation of the Proposed Strategic Equity Participation Plan;

(ii) Cengild Medical/UOBKH to furnish Bursa Securities with a certified true copy of the resolution passed pursuant to Sections 75 and 76 of the Act, in the event the existing authority has expired prior to the full implementation of the Proposed Strategic Equity Participation Plan;

(iii) Cengild Medical and UOBKH to inform Bursa Securities upon the completion of the Proposed Strategic Equity Participation Plan; and

(iv) Cengild Medical and UOBKH to furnish Bursa Securities with a written confirmation of its compliance with the terms and conditions of Bursa Securities' approval once the Proposed Strategic Equity Participation Plan is completed.

This announcement is dated 28 September 2026.